Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598992 | 0.86 | HSD17B10 (0.46) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL29953603 | 0.83 | HSD17B10 (0.56) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL1688876 | 0.82 | HSD17B10 (0.60) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL29563927 | 0.82 | HSD17B10 (0.60) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL547555 | 0.78 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL4944634 | 0.75 | THRB (0.52) | KMT2AMEN1ALDH1A1HSD17B10TSHR | |
| SCHEMBL12942838 | 0.74 | HSD17B10 (0.46) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL548664 | 0.74 | ERN1 (0.36) | KMT2AMEN1ALDH1A1HSD17B10KDM4E | |
| SCHEMBL547877 | 0.74 | WDR5 (0.61) | KMT2AMEN1ALDH1A1KDM4EWDR5 | |
| Benzene SCHEMBL28172839 | 0.73 | ALDH1A1 (0.55) | ALDH1A1HSD17B10KDM4ETSHRNR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| EP-1956054-B1 | Phase change ink | XEROX CORP (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1958993-A1 | Phase change inks containing colorant compounds | Xerox Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1956054-A2 | Colorant compounds | Xerox Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080187664-A1 | Phase change inks containing colorant compounds | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080184910-A1 | Mixture of basic dye and wax | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | KMT2A 1624/4885MEN1 685/4885ALDH1A1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.